• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致瘤性肝癌干细胞/祖细胞的鉴定与表征

Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

作者信息

Ma Stephanie, Chan Kwok-Wah, Hu Liang, Lee Terence Kin-Wah, Wo Jana Yim-Hung, Ng Irene Oi-Lin, Zheng Bo-Jian, Guan Xin-Yuan

机构信息

Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong, China.

出版信息

Gastroenterology. 2007 Jun;132(7):2542-56. doi: 10.1053/j.gastro.2007.04.025. Epub 2007 Apr 15.

DOI:10.1053/j.gastro.2007.04.025
PMID:17570225
Abstract

BACKGROUND & AIMS: Recent efforts in stem cell biology suggest that tumors are organized in a hierarchy of heterogeneous cell populations and that the capability to maintain tumor formation/growth specifically resides in a small population of cells called cancer stem cells (CSCs). The aim of this study is to identify, isolate, and characterize the CSC population that drives and maintains hepatocellular carcinoma (HCC) growth and metastasis.

METHODS

Normal stem cells involved in liver regeneration were identified using a severe partial hepatectomy model. Purified HCC cells, with or without expression of the identified normal stem cell phenotype, were evaluated, based on their tumorigenic potential and exhibition of defined stem/progenitor cell-like properties, to determine whether liver CSCs can be or partly be identified by this surface marker.

RESULTS

We report the identification and isolation of a population of CSCs expressing a CD133 surface phenotype from human liver cell lines. CD133(+) cells possess a greater colony-forming efficiency, higher proliferative output, and greater ability to form tumor in vivo. These cells are endowed with characteristics similar to those of progenitor cells including the expression of "stemness" genes, the ability to self-renew, and the ability to differentiate into nonhepatocyte-like lineages. Furthermore, CD133 is found to represent only a minority of the tumor cell population in human HCC specimens.

CONCLUSIONS

We report the identification of a CSC population in HCC characterized by their CD133 phenotype. The identification of tumorigenic liver CSCs could provide new insight into the HCC tumorigenic process and possibly bear great therapeutic implications.

摘要

背景与目的

干细胞生物学领域的最新研究表明,肿瘤是由异质性细胞群体组成的层级结构,维持肿瘤形成/生长的能力具体存在于一小部分被称为癌症干细胞(CSCs)的细胞中。本研究的目的是鉴定、分离并表征驱动和维持肝细胞癌(HCC)生长及转移的癌症干细胞群体。

方法

使用严重部分肝切除术模型鉴定参与肝脏再生的正常干细胞。基于其致瘤潜力以及所表现出的特定干细胞/祖细胞样特性,对表达或不表达所鉴定的正常干细胞表型的纯化肝癌细胞进行评估,以确定肝脏癌症干细胞是否可通过该表面标志物得以鉴定或部分鉴定。

结果

我们报告了从人肝癌细胞系中鉴定并分离出一群表达CD133表面表型的癌症干细胞。CD133(+)细胞具有更高的集落形成效率、更高的增殖能力以及更强的体内成瘤能力。这些细胞具有与祖细胞相似的特征,包括“干性”基因的表达、自我更新能力以及分化为非肝细胞样谱系的能力。此外,在人肝癌标本中发现CD133仅代表少数肿瘤细胞群体。

结论

我们报告了以CD133表型为特征的肝癌中癌症干细胞群体的鉴定。致瘤性肝脏癌症干细胞的鉴定可为肝癌的致瘤过程提供新的见解,并可能具有重大的治疗意义。

相似文献

1
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.致瘤性肝癌干细胞/祖细胞的鉴定与表征
Gastroenterology. 2007 Jun;132(7):2542-56. doi: 10.1053/j.gastro.2007.04.025. Epub 2007 Apr 15.
2
Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.乙醛脱氢酶可区分CD133肝癌干细胞群体。
Mol Cancer Res. 2008 Jul;6(7):1146-53. doi: 10.1158/1541-7786.MCR-08-0035.
3
miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.miR-130b 通过肿瘤抑制蛋白 53 诱导核蛋白 1 促进 CD133(+)肝肿瘤起始细胞的生长和自我更新。
Cell Stem Cell. 2010 Dec 3;7(6):694-707. doi: 10.1016/j.stem.2010.11.010.
4
CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.CD133(+) 肝癌起始细胞通过神经降压素/白细胞介素-8/CXCL1 信号促进肿瘤血管生成、生长和自我更新。
Hepatology. 2012 Mar;55(3):807-20. doi: 10.1002/hep.24739. Epub 2012 Jan 13.
5
Biology and clinical implications of CD133(+) liver cancer stem cells.CD133(+) 肝癌干细胞的生物学特性及其临床意义。
Exp Cell Res. 2013 Jan 15;319(2):126-32. doi: 10.1016/j.yexcr.2012.09.007. Epub 2012 Sep 19.
6
In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.在Hep-2细胞系中对CD133作为癌症干细胞假定标志物的体内研究。
Head Neck. 2009 Jan;31(1):94-101. doi: 10.1002/hed.20935.
7
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.肝癌中 CD133+CD44+ 细胞群高度富集癌症干细胞/祖细胞。
Int J Cancer. 2010 May 1;126(9):2067-78. doi: 10.1002/ijc.24868.
8
Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.将CD133 + 肝癌细胞鉴定为癌症干细胞/祖细胞。
Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4. doi: 10.1016/j.bbrc.2006.10.128. Epub 2006 Nov 2.
9
Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.肝癌细胞系的侧群细胞比例随肿瘤去分化而增加,但缺乏癌症干细胞的特征。
J Gastroenterol Hepatol. 2014 May;29(5):1092-101. doi: 10.1111/jgh.12484.
10
Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.ATOH8 的缺失增加了肝癌细胞的干细胞特征。
Gastroenterology. 2015 Oct;149(4):1068-81.e5. doi: 10.1053/j.gastro.2015.06.010. Epub 2015 Jun 20.

引用本文的文献

1
Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors.肝细胞癌干细胞:基于小分子抑制剂的研究现状
Cell Death Dis. 2025 Sep 1;16(1):666. doi: 10.1038/s41419-025-07983-5.
2
Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells.CD133抗体偶联纳米载体在增强肝癌干细胞靶向性中的作用
Sci Rep. 2025 Aug 19;15(1):30441. doi: 10.1038/s41598-025-14435-9.
3
Expression of DNAJB1-PRKACA oncogene suppresses the differentiation potential of liver progenitor organoids towards a hepatocyte lineage.
DNAJB1-PRKACA致癌基因的表达抑制了肝祖细胞类器官向肝细胞谱系的分化潜能。
Sci Rep. 2025 Jul 16;15(1):25796. doi: 10.1038/s41598-025-11028-4.
4
Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities.癌症干细胞与免疫疗法的关联:关键见解、挑战及潜在治疗机遇
Cancers (Basel). 2025 Jun 23;17(13):2100. doi: 10.3390/cancers17132100.
5
Brain Tumor Stem Cells: New Perspectives.脑肿瘤干细胞:新视角
Methods Mol Biol. 2025;2944:1-15. doi: 10.1007/978-1-0716-4654-0_1.
6
Identification of a Cancer Stem Cell-Related Gene Signature in Hepatocellular Carcinoma Based on Single-Cell RNA-Seq and Bulk RNA-Seq Analysis.基于单细胞RNA测序和批量RNA测序分析鉴定肝细胞癌中与癌症干细胞相关的基因特征
Int J Mol Sci. 2025 Mar 24;26(7):2933. doi: 10.3390/ijms26072933.
7
LAPTM4B enhances the stemness of CD133 liver cancer stem-like cells via WNT/β-catenin signaling.LAPTM4B通过WNT/β-连环蛋白信号通路增强CD133肝癌干细胞样细胞的干性。
JHEP Rep. 2024 Dec 20;7(4):101306. doi: 10.1016/j.jhepr.2024.101306. eCollection 2025 Apr.
8
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma.叶酸受体1是一种与肝细胞癌干性特征相关的诊断和预后标志物。
Biomark Res. 2025 Mar 4;13(1):37. doi: 10.1186/s40364-025-00752-8.
9
Farnesoid X Receptor Attenuates the Tumorigenicity of Liver Cancer Stem Cells by Inhibiting STAT3 Phosphorylation.法尼酯X受体通过抑制信号转导与转录激活因子3(STAT3)磷酸化减弱肝癌干细胞的致瘤性。
Int J Mol Sci. 2025 Jan 28;26(3):1122. doi: 10.3390/ijms26031122.
10
Liver oval cells in response to HDAC1 inhibitor trichostatin A: immunohistochemical characterization using OV-6 hepatic expression.肝卵圆细胞对组蛋白去乙酰化酶1抑制剂曲古抑菌素A的反应:利用OV-6肝脏表达进行免疫组织化学特征分析
Anat Cell Biol. 2025 Jun 30;58(2):247-263. doi: 10.5115/acb.24.231. Epub 2025 Jan 15.